{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:31Z","timestamp":1753891231538,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010816","name":"Anhui Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a type of highly heterogeneous mature B-cell malignancy with various disease courses. Although a multitude of prognostic markers in CLL have been reported, insights into the role of super-enhancer (SE)\u2013related risk indicators in the occurrence and development of CLL are still lacking. A super-enhancer (SE) is a cluster of enhancers involved in cell differentiation and tumorigenesis, and is one of the promising therapeutic targets for cancer therapy in recent years. In our study, the CLL-related super-enhancers in the training database were processed by LASSO-penalized Cox regression analysis to screen a nine-gene prognostic model including TCF7, VEGFA, MNT, GMIP, SLAMF1, TNFRSF25, GRWD1, SLC6AC, and LAG3. The SE-related risk score was further constructed and it was found that the predictive performance with overall survival and time-to-treatment (TTT) was satisfactory. Moreover, a high correlation was found between the risk score and already known prognostic markers of CLL. In the meantime, we noticed that the expressions of TCF7, GMIP, SLAMF1, TNFRSF25, and LAG3 in CLL were different from those of healthy donors (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). Moreover, the risk score and LAG3 level of matched pairs before and after treatment samples varied significantly. Finally, an interactive nomogram consisting of the nine-gene risk group and four clinical traits was established. The inhibitors of mTOR and cyclin-dependent kinases (CDKs) were considered effective in patients in the high-risk group according to the pRRophetic algorithm. Collectively, the SE-associated nine-gene prognostic model developed here may be used to predict the prognosis and assist in the risk stratification and treatment of CLL patients in the future.<\/jats:p>","DOI":"10.3389\/fgene.2022.1001364","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:48:19Z","timestamp":1663242499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Super-Enhancer\u2013Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Xue","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianfang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E686","DOI":"10.3390\/genes11060686","article-title":"Clinical relevance of +936 C>T VEGFA and c.233C>T bFGF polymorphisms in chronic lymphocytic leukemia","volume":"11","author":"Ballester","year":"2020","journal-title":"Genes (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1172\/JCI83013","article-title":"SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response","volume":"126","author":"Bologna","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: From genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"32061","DOI":"10.18632\/oncotarget.5201","article-title":"Expression and function of the TL1A\/DR3 axis in chronic lymphocytic leukemia","volume":"6","author":"Cavallini","year":"2015","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2012-03-416461","article-title":"Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression","volume":"120","author":"Chuang","year":"2012","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.v94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/gcc.20579","article-title":"Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia","volume":"47","author":"Fabris","year":"2008","journal-title":"Genes Chromosom. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2021","journal-title":"Int. J. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/leu.2009.98","article-title":"Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide\/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia","volume":"23","author":"Giannopoulos","year":"2009","journal-title":"Leukemia"},{"key":"B15","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/10428199609054782","article-title":"Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma","volume":"22","author":"Hallek","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fphar.2019.00361","article-title":"Targeting super-enhancers as a therapeutic strategy for cancer treatment","volume":"10","author":"He","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/leu.2011.125","article-title":"An eight-gene expression signature for the prediction of survival and time-to-treatment in chronic lymphocytic leukemia","volume":"25","author":"Herold","year":"","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/gcc.20879","article-title":"Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20","volume":"50","author":"Herold","year":"","journal-title":"Genes Chromosom. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/leu.2012.144","article-title":"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells","volume":"26","author":"Johnson","year":"2012","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3324\/haematol.2009.010298","article-title":"Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia","volume":"95","author":"Kienle","year":"2010","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2353\/jmoldx.2010.090100","article-title":"High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival","volume":"12","author":"Kotaskova","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"B24","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.2147\/CMAR.S214614","article-title":"Super-enhancer-associated hub genes in chronic myeloid leukemia identified using weighted gene Co-expression network analysis","volume":"11","author":"Ma","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1158\/1078-0432.CCR-10-0151","article-title":"Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion","volume":"16","author":"Mosca","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1038\/ncomms5532","article-title":"Speed control for neuronal migration in the postnatal brain by Gmip-mediated local inactivation of RhoA","volume":"5","author":"Ota","year":"2014","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"E2083","DOI":"10.3390\/molecules22122083","article-title":"Lipoprotein lipase expression in chronic lymphocytic leukemia: New insights into leukemic progression","volume":"22","author":"Prieto","year":"2017","journal-title":"Molecules"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1126\/science.285.5435.1923","article-title":"Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1","volume":"285","author":"Roose","year":"1999","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e28277","DOI":"10.1371\/journal.pone.0028277","article-title":"A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia","volume":"6","author":"Schweighofer","year":"2011","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1080\/10428194.2016.1239259","article-title":"The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group","volume":"58","author":"Seftel","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3324\/haematol.2008.002626","article-title":"Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA","volume":"94","author":"Stamatopoulos","year":"2009","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/leu.2009.176","article-title":"Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis","volume":"23","author":"Stamatopoulos","year":"2009","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1093\/nar\/gkv509","article-title":"Cdt1-binding protein GRWD1 is a novel histone-binding protein that facilitates MCM loading through its influence on chromatin architecture","volume":"43","author":"Sugimoto","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/15384101.2017.1338987","article-title":"GRWD1, a new player among oncogenesis-related ribosomal\/nucleolar proteins","volume":"16","author":"Takafuji","year":"2017","journal-title":"Cell Cycle"},{"key":"B37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/CBM-2012-0259","article-title":"Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia","volume":"11","author":"Trojani","year":"2011","journal-title":"Cancer Biomark."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41375-020-01025-z","article-title":"SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2","volume":"35","author":"von Wenserski","year":"2021","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11049","DOI":"10.7150\/thno.49168","article-title":"The emerging role of super enhancer-derived noncoding RNAs in human cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2147\/OTT.S290475","article-title":"Clinical significance and oncogenic activity of GRWD1 overexpression in the development of colon carcinoma","volume":"14","author":"Zhou","year":"2021","journal-title":"Onco. Targets. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/jcp.20570","article-title":"A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia","volume":"207","author":"Zucchetto","year":"2006","journal-title":"J. Cell. Physiol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1001364\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:48:25Z","timestamp":1663242505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1001364\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":42,"alternative-id":["10.3389\/fgene.2022.1001364"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.1001364","relation":{},"ISSN":["1664-8021"],"issn-type":[{"type":"electronic","value":"1664-8021"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"1001364"}}